Celgene Corporation (NASDAQ: CELG) reported a 56% jump in earnings for the third quarter of 2019 helped by higher revenue as well
Celgene Corporation
-(CELG)
XNAS:CELG
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Celgene Q2 profit beats estimates, lifts FY19 guidance
Celgene Corporation (NASDAQ: CELG) reported a 50% jump in earnings for the second quarter of 2019 helped by higher revenue as well
M&A alert: AbbVie agrees to acquire Allergan for $63 billion
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE:
Bristol-Myers lets go of psoriasis drug to save Celgene merger; stock falls
The planned merger between pharmaceutical firms Bristol-Myers Squibb Company (NYSE: BMY) and Celgene (CELG) - touted as a landmark deal in the
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
10 biggest US mergers & acquisitions announced so far in 2019
We are almost half-way into this year and the M&A market has not disappointed. We have seen a few massive deals so
Celgene stock jumps after advisory firm backs merger with Bristol-Myers Squibb
The planned acquisition of Celgene (CELG) by rival drugmaker Bristol-Myers Squibb (BMY) got a new lease of life this week after proxy
Celgene stock takes a dive after major Bristol-Myers stakeholder opposes merger deal
It's was a wild day for big pharma after Celgene Corp (CELG) slid at least 8% on early Thursday trade after one
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
Celgene posts upbeat Q4 results, guidance
Celgene Corp. (CELG) swung to a profit in the fourth quarter from a loss last year, helped by lower research and development
Microsoft-Walgreens deal highlights an emerging trend in healthcare sector
While the healthcare sector is witnessing a dramatic change in the way companies operate, marked by high-profile partnerships, the tech firms joining
In a massive deal, Eli Lilly acquires Loxo Oncology
Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology
Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges
Bristol-Myers Squibb (NYSE: BMY) acquired its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. Under the agreement terms, Celgene shareholders will